Biogen Inc. updated earnings guidance for full year 2022. For the period, the company now expects total revenue in the range of $9.9 billion to $10.1 billion as compared to $9.7 billion to $10 billion as previously guided.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
202.5 USD | +0.23% | +6.27% | -21.76% |
Apr. 25 | Goldman Sachs Adjusts Biogen Price Target to $340 From $393 | MT |
Apr. 25 | Canaccord Genuity Adjusts Price Target on Biogen to $308 From $305 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.76% | 29.48B | |
-4.66% | 87.53B | |
+2.63% | 40.42B | |
+56.34% | 25.43B | |
-14.78% | 15.59B | |
-18.49% | 11.49B | |
-15.61% | 11.1B | |
-44.02% | 11.3B | |
+4.34% | 8.75B | |
-8.19% | 7.99B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Biogen Inc. Updates Earnings Guidance for Full Year 2022